Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anja Seckinger

Showing results (61-70 of 122) with videos related to

Pageof 13
Sort By:
Blood|June 19, 2012
Clinical and prognostic role of annexin A2 in multiple myelomaAnja Seckinger, Tobias Meissner, Jérôme Moreaux, et al.
Plos One|January 4, 2014
The glycome of normal and malignant plasma cellsThomas M Moehler, Anja Seckinger, Dirk Hose, et al.
Haematologica|March 12, 2010
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantationKai Neben, Anna Jauch, Uta Bertsch, et al.
Blood Cancer Journal|September 5, 2023
Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survivalDaniela Simone Maichl, Julius Arthur Kirner, Susanne Beck, et al.
Cytometry. Part B, Clinical Cytometry|March 27, 2018
Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myelomaKatharina Kriegsmann, Tobias Dittrich, Brigitte Neuber, et al.
Experimental Hematology|March 30, 2006
The heterogeneity of human mesenchymal stem cell preparations--evidence from simultaneous analysis of proteomes and transcriptomesWolfgang Wagner, Robert E Feldmann, Anja Seckinger, et al.
Haematologica|July 11, 2019
Kinome expression profiling to target new therapeutic avenues in multiple myelomaHugues de Boussac, Angélique Bruyer, Michel Jourdan, et al.
Journal of Hematology & Oncology|June 28, 2019
Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trialDirk Hose, Susanne Beck, Hans Salwender, et al.
British Journal of Haematology|August 3, 2021
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-upMarco Basset, Christoph R Kimmich, Nicholas Schreck, et al.
Haematologica|November 28, 2015
Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myelomaNiels Weinhold, Desiree Kirn, Anja Seckinger, et al.
Pageof 13

Showing results (61-70 of 122) with videos related to

Sort By:
Pageof 13
Blood|June 19, 2012
Clinical and prognostic role of annexin A2 in multiple myelomaAnja Seckinger, Tobias Meissner, Jérôme Moreaux, et al.
Plos One|January 4, 2014
The glycome of normal and malignant plasma cellsThomas M Moehler, Anja Seckinger, Dirk Hose, et al.
Haematologica|March 12, 2010
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantationKai Neben, Anna Jauch, Uta Bertsch, et al.
Blood Cancer Journal|September 5, 2023
Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survivalDaniela Simone Maichl, Julius Arthur Kirner, Susanne Beck, et al.
Cytometry. Part B, Clinical Cytometry|March 27, 2018
Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myelomaKatharina Kriegsmann, Tobias Dittrich, Brigitte Neuber, et al.
Experimental Hematology|March 30, 2006
The heterogeneity of human mesenchymal stem cell preparations--evidence from simultaneous analysis of proteomes and transcriptomesWolfgang Wagner, Robert E Feldmann, Anja Seckinger, et al.
Haematologica|July 11, 2019
Kinome expression profiling to target new therapeutic avenues in multiple myelomaHugues de Boussac, Angélique Bruyer, Michel Jourdan, et al.
Journal of Hematology & Oncology|June 28, 2019
Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trialDirk Hose, Susanne Beck, Hans Salwender, et al.
British Journal of Haematology|August 3, 2021
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-upMarco Basset, Christoph R Kimmich, Nicholas Schreck, et al.
Haematologica|November 28, 2015
Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myelomaNiels Weinhold, Desiree Kirn, Anja Seckinger, et al.
Pageof 13